Download Files:
Products Details
Product Description
– HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC50: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC50 of 0.55 μM against 4T1 and an IC50 of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels[1].
Web ID
– HY-156096
Shipping
– Room temperature
Molecular Formula
– C16H21N5O2
References
– [1]Pulya S, et al. Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer. J Med Chem. 2023 Sep 14;66(17):12033-12058.. .
Molecular Weight
– 315.37
SMILES
– COC1=CC=C(CNC2=CN=C(C(NNCCC)=O)C=N2)C=C1
Clinical Information
– No Development Reported
Research Area
– cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;Caspase;HDAC;Histone Methyltransferase
Pathway
– Apoptosis;Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
